Publication Date

2011

Abstract

In this study, 250 women with osteoporosis were randomized to 12 months with subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg once weekly, then crossed over to the other treatment. The primary endpoint, treatment adherence at 12 months, was 76.6% for alendronate and 87.3% for denosumab.

School/Institute

Institute for Health and Ageing

Document Type

Journal Article

Access Rights

ERA Access

Access may be restricted.

Share

COinS